Last checked at 23 Feb 2017 07:00
23 February 2017
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
New monitor sales in USA and UK
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has received confirmation of monitor orders worth over £0.2m which, as indicated in the trading update announced on 18 January 2017 had moved into 2017 due to the rescheduling of capital allocations in a small number of hospitals.
The largest value sales contract is from the USA for six monitors from a seven hospital system in the Company's Great Lakes sales territory. The customer had originally planned to start implementation of ODM within its flagship hospital from April 2016 but, following delays in its procurement processes, has now decided to start implementation simultaneously in two additional hospitals.
The other major order is for 13 monitors from a consortium of NHS hospitals in the UK, comprising replacements for nine previously purchased monitors and four additional units.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"We are encouraged that we have been able to secure capital funding for our ODM monitors from major customers in both the USA and UK at a time of restricted capital budgets. The US sales contract means we can now move forward with supporting implementation of ODM in one of the most presitigious of the US platform accounts we announced in 2016."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Financial Public Relations | |
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.